Tumor Biology

, Volume 37, Issue 5, pp 6315–6321 | Cite as

Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion

Original Article
First Online:
Received:
Accepted:

Abstract

Wnt signaling is essential for the initiation and progression of osteosarcoma (OS) tumors and is suppressed by the secreted frizzled-related proteins (SFRPs). The methylation-induced protein degradation reduces the activity of SFRPs and subsequently increases the activity of Wnt signaling. However, whether the methylation of SFRP2, a member of SFRPs, may be involved in the pathogenesis of OS is not known. Here, we investigated the expression levels of SFRP2 in OS specimens. We found that SFRP2 mRNA was significantly decreased and methylation of SFRP2 gene was significantly increased in malignant OS tumors as compared to the paired adjacent non-tumor tissue. Moreover, SFRP2 expression was significantly decreased in the malignant OS cell lines, SAOS2, MG63, and U2OS, but not in the primary osteoblast cells. The demethylation of SFRP2 gene by 5′-aza-deoxycytidine (5-aza-dCyd) in OS cell lines restored SFRP2 expression, at both mRNA and protein levels, and suppressed cell invasion. Furthermore, the demethylation of SFRP2 gene appeared to inhibit nuclear retention of a key Wnt signaling factor, β-catenin, in OS cell lines. Together, these data suggest that SFRP2 may function as an OS invasion suppressor by interfering with Wnt signaling, and the methylation of SFRP2 gene may promote pathogenesis of OS.

Keywords

Osteosarcoma (OS) Secreted frizzled-related proteins (SFRPs) Methylation 5-aza-dCyd Wnt signaling β-catenin Cancer invasion 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by National Grant of The Education Department of Liaoning Province (No: L2014336).

Compliance with ethical standards

Conflicts of interest

The authors have declared that no competing interests exist.

References

  1. 1.
    Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S. Frequent epigenetic inactivation of sfrp genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 2007;26:4699–713.CrossRefPubMedGoogle Scholar
  2. 2.
    Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Lin R, Feng J, Dong S, Pan R, Zhuang H, Ding Z. Regulation of autophagy of prostate cancer cells by beta-catenin signaling. Cell Physiol Biochem. 2015;35:926–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Xu X, Ma J, Li C, Zhao W, Xu Y. Regulation of chondrosarcoma invasion by MMP26. Tumour Biol. 2015;36:365–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Liu S, Chen M, Li P, Wu Y, Chang C, Qiu Y, et al. Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. Cell Physiol Biochem. 2015;36:499–508.CrossRefPubMedGoogle Scholar
  6. 6.
    Ge Z, Zhang B, Bu X, Wang Y, Xiang L, Tan J. Molecular mechanism of activating protein-4 regulated growth of hepatocellular carcinoma. Tumour Biol. 2014;35:12441–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang H, Liu C, Kong Y, Huang H, Wang C, Zhang H. Tgfbeta signaling in pancreatic ductal adenocarcinoma. Tumour Biol. 2015;36:1613–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res. 1998;18:657–66.PubMedGoogle Scholar
  9. 9.
    Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.CrossRefPubMedGoogle Scholar
  10. 10.
    Li G, Fu D, Liang W, Fan L, Chen K, Shan L, et al. Cyc1 silencing sensitizes osteosarcoma cells to trail-induced apoptosis. Cell Physiol Biochem. 2014;34:2070–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Liu Y, He J, Chen X, Li J, Shen M, Yu W, et al. The proapoptotic effect of formononetin in human osteosarcoma cells: involvement of inactivation of ERK and Akt pathways. Cell Physiol Biochem. 2014;34:637–45.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang Q, Cai J, Wang J, Xiong C, Zhao J. MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 2014;35:12743–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Xiao Q, Zhang X, Wu Y, Yang Y. Inhibition of macrophage polarization prohibits growth of human osteosarcoma. Tumour Biol. 2014;35:7611–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Luo XJ, Tang DG, Gao TL, Zhang YL, Wang M, Quan ZX, et al. MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4. Cell Physiol Biochem. 2014;34:2180–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Li F, Li S, Cheng T. Tgf-beta1 promotes osteosarcoma cell migration and invasion through the miR-143-versican pathway. Cell Physiol Biochem. 2014;34:2169–79.CrossRefPubMedGoogle Scholar
  16. 16.
    He Y, Meng C, Shao Z, Wang H, Yang S. MiR-23a functions as a tumor suppressor in osteosarcoma. Cell Physiol Biochem. 2014;34:1485–96.CrossRefPubMedGoogle Scholar
  17. 17.
    Chen J, Fu H, Wang Z, Yin F, Li J, Hua Y, et al. A new synthetic ursolic acid derivative IUA with anti-tumor efficacy against osteosarcoma cells via inhibition of JNK signaling pathway. Cell Physiol Biochem. 2014;34:724–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Xu H, Liu X, Zhao J. Down-regulation of miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem. 2014;33:1547–56.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu G, Wang J, Jia Y, Shen F, Han W, Kang Y. Mir-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1. Cell Physiol Biochem. 2014;33:1329–39.CrossRefPubMedGoogle Scholar
  20. 20.
    Pan W, Wang H, Jianwei R, Ye Z. MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2k4 in human osteosarcoma cells. Cell Physiol Biochem. 2014;33:402–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen X, Luther G, Zhang W, Nan G, Wagner ER, Liao Z, et al. The E-F hand calcium-binding protein S100A4 regulates the proliferation, survival and differentiation potential of human osteosarcoma cells. Cell Physiol Biochem. 2013;32:1083–96.CrossRefPubMedGoogle Scholar
  22. 22.
    Chang YW, Zhao YF, Cao YL, Gu XF, Li ZQ, Wang SQ, et al. Liver x receptor alpha inhibits osteosarcoma cell proliferation through up-regulation of FoxO1. Cell Physiol Biochem. 2013;32:180–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Pinto D, Clevers H. Wnt, stem cells and cancer in the intestine. Biol Cell. 2005;97:185–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013;25:254–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Ehrlund A, Mejhert N, Lorente-Cebrian S, Astrom G, Dahlman I, Laurencikiene J, et al. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPS) in human adipose tissue. J Clin Endocrinol Metab. 2013;98:E503–508.CrossRefPubMedGoogle Scholar
  26. 26.
    Shin H, Kim JH, Lee YS, Lee YC. Change in gene expression profiles of secreted frizzled-related proteins (SFRPS) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling. Int J Oncol. 2012;40:1533–42.PubMedGoogle Scholar
  27. 27.
    Nathan E, Tzahor E. sFRPS: a declaration of (Wnt) independence. Nat Cell Biol. 2009;11:13.CrossRefPubMedGoogle Scholar
  28. 28.
    Drescher U. A no-Wnt situation: SFRPS as axon guidance molecules. Nat Neurosci. 2005;8:1281–2.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhang Y, Chen H. Genistein attenuates WNT signaling by up-regulating sFRP2 in a human colon cancer cell line. Exp Biol Med (Maywood). 2011;236:714–22.CrossRefGoogle Scholar
  30. 30.
    Chung MT, Lai HC, Sytwu HK, Yan MD, Shih YL, Chang CC, et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol. 2009;112:646–53.CrossRefPubMedGoogle Scholar
  31. 31.
    Sui C, Ma J, Chen Q, Yang Y. The variation trends of SFRP2 methylation of tissue, feces, and blood detection in colorectal cancer development. Eur J Cancer Prev. 2015. doi:  10.1097/CEJ.0000000000000185
  32. 32.
    Zhang X, Song YF, Lu HN, Wang DP, Zhang XS, Huang SL, et al. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 2015;21:2629–37.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sui C, Wang G, Chen Q, Ma J. Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer. Tumour Biol. 2014;35:10457–65.CrossRefPubMedGoogle Scholar
  34. 34.
    Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E, et al. Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama. 2011;65:169–77.PubMedGoogle Scholar
  35. 35.
    Pehlivan S, Artac M, Sever T, Bozcuk H, Kilincarslan C, Pehlivan M. Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Genet Cytogenet. 2010;201:128–32.CrossRefPubMedGoogle Scholar
  36. 36.
    Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 2008;14:524–31.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Huang Z, Li L, Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci. 2007;52:2287–91.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Hand SurgeryThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina

Personalised recommendations